Jason Baybutt - Artelo Biosciences Senior Finance
| ARTL Stock | USD 1.10 0.01 0.90% |
Executive
Jason Baybutt is Senior Finance of Artelo Biosciences
| Age | 52 |
| Address | 505 Lomas Santa Fe, Solana Beach, CA, United States, 92075 |
| Phone | 858 925 7049 |
| Web | https://www.artelobio.com |
Artelo Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5433) % which means that it has lost $0.5433 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8858) %, meaning that it created substantial loss on money invested by shareholders. Artelo Biosciences' management efficiency ratios could be used to measure how well Artelo Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.51. Return On Capital Employed is expected to rise to -0.58 this year. At this time, Artelo Biosciences' Intangibles To Total Assets are quite stable compared to the past year. Debt To Assets is expected to rise to 0.01 this year, although the value of Non Current Assets Total will most likely fall to about 1.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD III | Akari Therapeutics PLC | 71 | |
| Gerrit Hauck | Basilea Pharmaceutica AG | 59 | |
| John Leonard | Vaccinex | 77 | |
| Laurenz Kellenberger | Basilea Pharmaceutica AG | 56 | |
| Charles Garner | Aileron Therapeutics | 48 | |
| Reinhard MD | Curis Inc | N/A | |
| MPH MD | Salarius Pharmaceuticals | N/A | |
| Ernest Smith | Vaccinex | 52 | |
| Jonathan Zung | Curis Inc | 59 | |
| David Veitch | Basilea Pharmaceutica AG | 58 | |
| Patrick Ryan | Nutriband Warrant | 38 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Graeme Currie | Pasithea Therapeutics Corp | 57 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Jeffrey PharmD | Nutriband Warrant | 54 | |
| BethAnne Lang | Akari Therapeutics PLC | N/A | |
| Jill CPA | Vaccinex | 52 | |
| Mark Noel | Curis Inc | 65 | |
| Jill Sanchez | Vaccinex | 52 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
Management Performance
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.54 |
Artelo Biosciences Leadership Team
Elected by the shareholders, the Artelo Biosciences' board of directors comprises two types of representatives: Artelo Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Artelo. The board's role is to monitor Artelo Biosciences' management team and ensure that shareholders' interests are well served. Artelo Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Artelo Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jason Baybutt, Senior Finance | ||
| Andrew Yates, Senior Officer | ||
| Steven Reich, Chief Officer | ||
| Gregory MBA, CEO and President |
Artelo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Artelo Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | (1.19 M) | ||||
| Shares Outstanding | 3.23 M | ||||
| Shares Owned By Insiders | 0.82 % | ||||
| Shares Owned By Institutions | 0.70 % | ||||
| Number Of Shares Shorted | 19.93 K | ||||
| Price To Earning | 16.31 X | ||||
| Price To Book | 0.56 X | ||||
| EBITDA | (7.44 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Return On Assets (0.54) | Return On Equity (0.89) |
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.